Sign inCreate account

Report workspace tools

NCT05559801NOT_YET_RECRUITINGanonymous

A Phase 1/2 Study to Examine the Safety and Preliminary Efficacy of Mesenchymal Stromal Cells on Linear Growth and Bone Health Parameters in Children With Type 3 Osteogenesis Imperfecta (OI)

Sponsor

Source record

Emory University

Phase

Source record

PHASE1

Modality

AI-normalized

gene therapy

Target

AI-normalized

Bone marrow-derived mesenchymal stromal cells (MSCs)

Indication / condition

AI-normalized

Osteogenesis Imperfecta

Intervention

Source record

Bone marrow-derived mesenchymal stromal cells (MSCs)

Source & freshness

Source record

NCT ID

NCT05559801

Original source

ClinicalTrials.gov

Source last updated

May 08, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05559801

Title

A Phase 1/2 Study to Examine the Safety and Preliminary Efficacy of Mesenchymal Stromal Cells on Linear Growth and Bone Health Parameters in Children With Type 3 Osteogenesis Imperfecta (OI)

Sponsor

Emory University

Status

NOT_YET_RECRUITING

Phase

PHASE1

Condition raw

Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III

Condition normalized

Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III

Modality raw

gene therapy

Modality normalized

gene therapy

Target raw

Bone marrow-derived mesenchymal stromal cells (MSCs)

Target normalized

Bone marrow-derived mesenchymal stromal cells (MSCs)

Interventions

Bone marrow-derived mesenchymal stromal cells (MSCs)

Public preview

Source record

This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1/2 Study to Examine the Safety and Preliminary Efficacy of Mesenchymal Stromal Cells on Linear Growth and Bone Health Parameters in Children With Type 3 Osteogenesis Imperfecta (OI)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05559801

Status

NOT_YET_RECRUITING

Phase

PHASE1

Sponsor

Emory University

Executive brief

Investment-Ready Snapshot

This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 08, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05559801

Indication

Osteogenesis Imperfecta

Modality

gene therapy

Target

Bone marrow-derived mesenchymal stromal cells (MSCs)

Intervention

Bone marrow-derived mesenchymal stromal cells (MSCs)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.